Liposomal Formulation of a Melphalan Lipophilic Prodrug: Studies of Acute Toxicity, Tolerability, and Antitumor Efficacy

Daria Tretiakova, E. V. Svirshchevskaya, Natalia Onishchenko, Anna Alekseeva, Ivan Boldyrev, Roman Kamyshinsky, Alexey Natykan, Anton Lokhmotov, Diana Arantseva, D. L. Shobolov

Current Drug Delivery · 2020 · 14 citations · 38 references

Abstract

Lower toxicity of the liposomal formulation of MlphDG promises improved quality of life for cancer patients in need of treatment with melphalan. Presumably, the list of indications for melphalan therapy could be extended.

References

38